Ciclosporin A proof of concept study in patients with active, progressive HTLV-1 associated myelopathy/tropical spastic paraparesis.

This showed a trend towards improvement compared to baseline at 12 weeks with a mean (SE) decrease in score of −7 (5), p = 0.24 (ITT, Table 2 ), which was maintained to week 48 and to week 72 (after treatment had stopped), by ITT and PP analysis ( Figure 3 ).

also in 53,322 other papers

Spasticity (MASS) improved at all time points compared to baseline, with a decrease in score of −0.3 or −0.4, although changes did not reach statistical significance ( Figure 4 , Table 2 ).

also in 111,027 other papers